Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$24.7M Buy
185,000
+80,000
+76% +$9.05M 3.47% 7
2026
Q1
$11.7M Buy
105,000
+57,000
+119% +$6.75M 3.42% 8
2025
Q4
$6.47M Buy
48,000
+8,000
+20% +$873K 1.86% 12
2025
Q3
$3.4M Buy
+40,000
New +$2.45M 1.34% 15

Other funds holding ABVX

Findell Capital Management's ABVX Position: Q2 2026 in Review

Findell Capital Management increased its Abivax (ABVX) stake by 76% in Q2 2026, buying an estimated $9.05M and bringing the position to 185,000 shares worth $24.7M. The position accounts for 3.47% of the portfolio, ranked #7.

Findell Capital Management first reported a position in ABVX in Q3 2025 and has held it in 4 quarters since. 303 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Findell Capital Management held 185,000 shares of Abivax worth $24.7M as of Q2 2026.
  • Findell Capital Management bought 80,000 Abivax shares in Q2 2026, an estimated $9.05M.
  • Abivax made up 3.47% of Findell Capital Management's portfolio in Q2 2026, its #7 holding.
  • Findell Capital Management first reported a position in Abivax in Q3 2025 and has held it in 4 quarters since.
  • 303 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Findell Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.